JP4737931B2 - 医薬品の製造におけるヒドロキシオレイン酸及び類似化合物の使用 - Google Patents

医薬品の製造におけるヒドロキシオレイン酸及び類似化合物の使用 Download PDF

Info

Publication number
JP4737931B2
JP4737931B2 JP2003533923A JP2003533923A JP4737931B2 JP 4737931 B2 JP4737931 B2 JP 4737931B2 JP 2003533923 A JP2003533923 A JP 2003533923A JP 2003533923 A JP2003533923 A JP 2003533923A JP 4737931 B2 JP4737931 B2 JP 4737931B2
Authority
JP
Japan
Prior art keywords
acid
protein
hydroxyoleic acid
analogs
hydroxyoleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003533923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005527479A (ja
JP2005527479A5 (enExample
Inventor
ルイス、パブロ、ヴィチェンテ エスクリバ
Original Assignee
ユニベルシタト デ レス イルレス バレアルス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニベルシタト デ レス イルレス バレアルス filed Critical ユニベルシタト デ レス イルレス バレアルス
Publication of JP2005527479A publication Critical patent/JP2005527479A/ja
Publication of JP2005527479A5 publication Critical patent/JP2005527479A5/ja
Application granted granted Critical
Publication of JP4737931B2 publication Critical patent/JP4737931B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003533923A 2001-10-11 2002-10-09 医薬品の製造におけるヒドロキシオレイン酸及び類似化合物の使用 Expired - Lifetime JP4737931B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200102269A ES2186576B1 (es) 2001-10-11 2001-10-11 Acido 2-hidroxioleico para utilizar como medicamento.
ESP200102269 2001-10-11
PCT/ES2002/000475 WO2003030891A1 (es) 2001-10-11 2002-10-09 Utilizacion del acido hidroxioleico y compuestos analogos del mismo en la fabricacion de medicamentos

Publications (3)

Publication Number Publication Date
JP2005527479A JP2005527479A (ja) 2005-09-15
JP2005527479A5 JP2005527479A5 (enExample) 2006-01-05
JP4737931B2 true JP4737931B2 (ja) 2011-08-03

Family

ID=8499164

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003533923A Expired - Lifetime JP4737931B2 (ja) 2001-10-11 2002-10-09 医薬品の製造におけるヒドロキシオレイン酸及び類似化合物の使用

Country Status (13)

Country Link
US (3) US20050014831A1 (enExample)
EP (1) EP1435235B1 (enExample)
JP (1) JP4737931B2 (enExample)
CN (3) CN101259122B (enExample)
AT (1) ATE322261T1 (enExample)
BR (1) BRPI0213165B8 (enExample)
CA (1) CA2463348C (enExample)
DE (1) DE60210488T2 (enExample)
ES (2) ES2186576B1 (enExample)
MX (1) MXPA04003255A (enExample)
PT (1) PT1435235E (enExample)
RU (1) RU2310445C2 (enExample)
WO (1) WO2003030891A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2229935B1 (es) * 2003-10-10 2006-10-01 Universitat De Les Illes Balears Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales.
JP2009051732A (ja) * 2005-12-13 2009-03-12 Meiji Seika Kaisha Ltd Ｐｐａｒリガンド活性を有する組成物
CN101570481B (zh) * 2008-04-30 2012-02-01 上海医药工业研究院 一种多羟基长链脂肪酸及其分离提取方法和在抑制芳香化酶活性中的应用
ES2342997B1 (es) * 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
WO2011089265A1 (en) 2010-01-25 2011-07-28 Bridge Bioresearch Plc Use of fatty acid compounds for lowering blood glucose levels
CN101985420B (zh) * 2010-01-29 2014-04-30 苏州润新生物科技有限公司 油酸酯及其制备方法和在制备用于治疗高血压及其并发症的药物中的应用
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
JP6053695B2 (ja) * 2012-01-19 2016-12-27 日本水産株式会社 食欲抑制剤
WO2013132092A1 (en) 2012-03-09 2013-09-12 Pensieve International Plc Use of monounsaturated fatty acid compounds for controlling the body weight of a dog or a cat
ES2734554T3 (es) * 2012-09-26 2019-12-10 Tangent Reprofiling Ltd Combinación de benzo(iso)oxazolpiperidinas con ácido linoleico conjugado
GB201217296D0 (en) 2012-09-27 2012-11-14 Alta Innovations Ltd Method of treatment and/or prevention
RU2679443C2 (ru) * 2014-10-21 2019-02-11 Университат Де Лес Ильес Балеарс Способ синтеза гидрокситриглицеридов и их применение для профилактики и лечения заболеваний
US10756968B2 (en) 2015-01-26 2020-08-25 Rapid7, Inc. Network resource management devices methods and systems

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61297A (ja) * 1984-06-12 1986-01-06 日本油脂株式会社 オレイン酸の製造法
GB8603621D0 (en) * 1986-02-14 1986-03-19 Habib N Modifying lipid structure of cell membranes
JPS6344843A (ja) * 1986-08-13 1988-02-25 Kao Corp 油中水中油型乳化油脂組成物
CN1035925C (zh) * 1988-11-16 1997-09-24 许正 亲细胞非均质分子脂质的制备方法
US5422371A (en) * 1992-05-27 1995-06-06 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
CN1118228A (zh) * 1995-03-16 1996-03-13 姜训书 松籽果酱
CN1118218A (zh) * 1995-03-16 1996-03-13 姜训书 松籽油的制作方法及松籽保健食用油
GB9506837D0 (en) * 1995-04-03 1995-05-24 Scotia Holdings Plc Triglycerides
DK0771817T3 (da) * 1995-10-30 2003-07-28 Oleoyl Estrone Developments S Oleatmonoestere af østrogener til behandling af obesitet og/eller overvægt
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
DE19727636C1 (de) * 1997-06-28 1998-11-19 Rwe Dea Ag Verfahren zur Herstellung von 2-Alkylcarbonsäuren
CN1212867A (zh) * 1997-09-29 1999-04-07 宋凤亭 防治心脑血管疾病的组合物
US6077867A (en) * 1998-01-21 2000-06-20 Fideline Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
US6214875B1 (en) * 1998-04-14 2001-04-10 Zhenhua Yang Anticancer effects of specific branched-chain fatty acids and related production process
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
GB2389788B (en) * 2000-12-23 2005-07-20 Univ Creighton Methods for inducing apoptosis and inhibiting proliferation in cancer cells
DE10130491A1 (de) * 2001-06-25 2003-04-17 Heirler Horst Verwendung von mittelkettigen Triglyceriden zur Prävention und Therapie von Adipositas

Also Published As

Publication number Publication date
PT1435235E (pt) 2006-08-31
US20110136906A1 (en) 2011-06-09
CN101259122B (zh) 2011-04-06
WO2003030891A1 (es) 2003-04-17
ES2261752T3 (es) 2006-11-16
ES2186576A1 (es) 2003-05-01
EP1435235B1 (en) 2006-04-05
US7851507B2 (en) 2010-12-14
US20090082446A1 (en) 2009-03-26
CN1688302A (zh) 2005-10-26
ES2186576B1 (es) 2004-09-16
CN101259122A (zh) 2008-09-10
BRPI0213165B1 (pt) 2018-01-23
JP2005527479A (ja) 2005-09-15
CN101259121A (zh) 2008-09-10
CN100471492C (zh) 2009-03-25
CA2463348C (en) 2011-04-05
BR0213165A (pt) 2004-09-14
EP1435235A1 (en) 2004-07-07
MXPA04003255A (es) 2005-01-25
CN101259121B (zh) 2011-04-06
DE60210488D1 (de) 2006-05-18
ATE322261T1 (de) 2006-04-15
US20050014831A1 (en) 2005-01-20
RU2004114229A (ru) 2005-04-20
CA2463348A1 (en) 2003-04-17
DE60210488T2 (de) 2006-12-14
US8778995B2 (en) 2014-07-15
RU2310445C2 (ru) 2007-11-20
BRPI0213165B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
US7851507B2 (en) Use of hydroxyoleic acid and related compounds in the manufacture of drugs
ES2363442T3 (es) Combinación que comprende al menos una aminoácido y un inhibidor de pkr para utilizar en el tratamiento de la pérdida de masa muscular.
AU2018392985A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
US20190274979A2 (en) Use of (benzenesulfonamido)benzamide compounds for inhibiting liver fibrosis
WO2020132378A2 (en) Compositions and methods of treatment for neurological disorders comprising depression
WO2023030687A1 (en) Cyclopenta[4,5]furo[3,2-c]pyridine derivatives as ras inhibitors for use in the treatment of hyperproliferative diseases or genetic disorders
US20150328186A1 (en) Methods of Treating Hepatic Fibrosis and Associated Diseases by Regulating Rev-ERB Activity
WO2004093910A1 (ja) ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
CN101316584A (zh) 用于预防及治疗由血管通透性亢进引起的眼病的医药
US11850234B2 (en) Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway
US20150157588A1 (en) Pharmaceutical Composition Comprising Amino-Phenyl-Acetic Acid Octadec-(Z)-9-enyl Ester and Use Thereof for Treating Tumors
WO2016070798A1 (zh) 一种抑制脂肪细胞分化和胰岛素耐受的药物
US12012415B2 (en) Compositions and methods for the diagnosis, treatment and prevention of neoplastic and neurological disorders
KR20240127619A (ko) N-포르밀트립톨린을 유효성분으로 포함하는 방사선 내성 암의 예방, 개선 또는 치료용 조성물
WO2023242106A1 (en) Novel ras inhibitors
AU2023293888A1 (en) Mitoxanthrone derivatives as ras inhibitors
JP3981739B2 (ja) 抗癌剤、癌細胞の増殖を抑制する方法
CN120826226A (zh) 新型混合物作为ras抑制剂治疗增殖性和遗传性疾病的用途
WO2023242103A1 (en) Novel ras inhibitors
JPWO2004056351A1 (ja) Ｐｋａ活性調節剤
HUP0400255A2 (hu) Retinoid receptor ligandumok és kiválasztott citotoxikus szerek szinergikus kombinációi rák kezelésére
JPWO2009128395A1 (ja) ２−アミノフェノール又はその誘導体を有効成分とする骨形成促進剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090611

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090710

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090812

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110124

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110408

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110426

R150 Certificate of patent or registration of utility model

Ref document number: 4737931

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140513

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term